Visit this space regularly to stay informed on the latest happenings at all our locations! You’ll also find our latest press releases and publications for learning and sharing what’s new at Fenway.
October 13, 2025
Due to a change in federal requirements that went into effect October 1, 2025, Fenway Health is unable to provide medical gender-affirming care (hormones and puberty blockers) for patients under the age of 19. All other care and services for patients of all ages and backgrounds will remain available and unchanged, at this time.
This change in position is a response to a shifting federal landscape that requires us to adapt in order to remain compliant, sustainable, and able to provide healthcare, support, and services to all our patients and the community. Fenway Health is a federally qualified health center (FQHC), and we are required to maintain compliance with HRSA regulations. Being an FQHC allows us to continue delivering high-quality comprehensive care for more than 30,000 residents of New England and beyond. Losing this status would challenge our ability to meet the needs of all who rely on us.
Our priority through this process, and always, is to center patients by focusing on the health, safety, and continuity of care of those impacted as well as our broader patient population as we navigate these new federal requirements.
Christopher Viveiros
Director of Communications
617.927.6342
Email
Want to receive news and updates from Fenway Health? Sign up here!
As backpacks get packed and pencils get sharpened, don’t forget one of the most important school supplies—clear vision! Our elite team of Optometrists at Fenway Health are equipped to see patients
Fenway Health is excited to join in the nationwide celebration of America’s 1,400 community health centers (CHCs) during National Health Center Week 2025. Taking place August 3–9, this annual event honors the
We are very happy to share that Fenway has once again successfully renewed our NCQA Patient Centered Medical Home (PCMH) Recognition for our location at 1340 Boylston Street in Boston as
Fenway Health is proud to share that the FDA has just approved YEZTUGO, the first long-acting injectable PrEP medication administered just twice a year. This is a major milestone in the effort
Fenway Health joins healthcare organizations across the country in commending the Supreme Court’s decision in Kennedy v. Braidwood to protect Affordable Care Act (ACA) requirements that private insurers cover preventive health
On June 18, the US Food and Drug Administration (FDA) approved the use of Gilead’s anti-HIV medication, Lenacapravir (trade name: Yeztugo) as a twice-yearly subcutaneous injection for pre-exposure prophylaxis (PrEP) for
